|Bid||1.6600 x 1100|
|Ask||1.6700 x 900|
|Day's Range||1.6200 - 1.6900|
|52 Week Range||0.6500 - 8.4000|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.67|
vTv Therapeutics Inc. (VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal azeliragon plasma concentrations of less than 7.5 ng/mL and baseline Mini Mental State Examination (MMSE) scores between 19 and 27, and the endpoints were statistically significant improvement in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) at 12-months compared to placebo.
NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avangrid, ...
A deal that he had signed in December compelled him to buy vTv shares on May 24 for nearly three times the market price that day. MacAndrews & Forbes, an investment vehicle of which Perelman is the chairman, chief executive, and sole shareholder, agreed Dec. 5 to buy up to $10 million in vTv shares at $4.38 each for a period of one year—at the request of the biotech. The $4.38 exercise price was determined by the average of the volume-weighted average prices of vTv shares for the five trading days preceding Dec. 5.
High Point-based vTv Therapeutics has inked an agreement with a Chinese company for rights to develop and commercialize a drug candidate aimed at respiratory and other inflammatory diseases. China’s Newsoara Biopharma Co. Ltd. has acquired rights for HPP737, a selective phosphodiesterase type 4 (PDE4) inhibitor, that has shown therapeutic activity in several animal models for inflammation. It will be able to commercialize the product in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea.
vTv Therapeutics Inc. (VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea. Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Newsoara will develop HPP737 in the covered territories for respiratory and other inflammatory diseases.
Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.
On a per-share basis, the High Point, North Carolina-based company said it had a loss of 30 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
vTv Therapeutics Inc. today reported financial and operational results for the first quarter that ended March 31, 2018.
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing ...
vTv Therapeutics Inc. (VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease, despite not meeting co-primary endpoints, identified a subpopulation that showed statistically significant benefit (unadjusted for multiple, post hoc comparisons) from azeliragon relative to placebo on ADAS-cog. Based on the subpopulation data analyses from the Part A study and the prior azeliragon trials, the company will submit a revised Statistical Analysis Plan (SAP) to the Food and Drug Administration for the Part B Study that pre-specifies a target population for the primary study analysis and expects to report Part B topline efficacy results based on 12 month data in June 2018.
The executive is leaving about three weeks after the clinical stage pharmaceutical company announced disappointing trial results for one of its key drug prospects that was aimed at Alzheimer's.
Shares of InVivo also headed higher after a reverse stock split this week. InVivo is also in the process of finalizing a lease assignment that the company expects will result in lease-related savings of approximately $3M through 2019.
The prospect of vTv Therapeutics moving its office was raised after it was revealed Cambrex Corp. bought the building. The company is also ending clinical trials for an Alzheimer's drug it has been developing.
It's the first day the stock hit above $1 since vTv Therapeutics reported disappointing results from the Phase 3 study of its drug azeliragon.
Cambrex has taken steps toward another expansion by buying up two buildings for $10.2 million.
vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.
vTv Therapeutics Inc (NASDAQ: VTVT ) announced Monday after the close that results from Part A of its late-stage study of an investigational medication to treat Alzheimer's disease did not meet either ...
Shares of vTv Therapeutics Inc. plunged in the extended session Monday after the drug developer said a late-stage clinical trial of its Alzheimer's disease treatment did not meet study goals. Shares of ...
vTv Therapeutics, Inc. today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary efficacy endpoint.
Stock Monitor: BioLine Rx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT ). If you ...
The study is underway through a partnership with JDRF, with both of the companies putting up $3 million each for the assessment.
vTv Therapeutics Inc. today announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in adult patients with type 1 diabetes .
vTv Therapeutics Inc (NASDAQ: VTVT ) shares have outperformed Axovant Sciences Ltd (NASDAQ: AXON ) shares by 63 percent since Chardan recommended owning the former over the latter in January 2016. The ...